Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer.
Today, Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the 2022 American Society of Clinical
Sarah Cannon to Present Latest Oncology Research Insights at 2022 ASCO® Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.